

Antimicrobial Activity of Substituted Thiazoles Against MRSA

Track Code: 2013-CUSH-66348

Categories:

- Medical/Health

Keywords:

- Medical/Health
- Medicinal Chemistry
- MRSA

Methicillin-resistant *Staphylococcus aureus* (MRSA) is a global health concern due to its high mortality rate and ability to spread rapidly. For the year 2012, a study by the Centers for Disease Control (CDC) found that 18.74 percent of patients in US healthcare facilities were infected or colonized with MRSA, contributing to an estimated 8,128 deaths from healthcare associated (HCA) infections. In addition, many treatments previously used against MRSA are no longer effective due to the development of microbial resistance to these antibiotics. Consequently, there is currently a dearth of effective treatments for MRSA. Given the severity of MRSA infections, attributed health care costs are estimated between \$3 billion and \$4 billion per year.

Researchers at Purdue University found that a class of chemicals known as thiazoles could be substituted with specific molecular groups to be effective antimicrobials against MRSA and other microorganisms including *listeria monocytogenes* and *bacillus anthracis*. These chemicals were shown to inhibit the growth of MRSA cells in broth microdilution trials; furthermore, they were shown to be noncytotoxic to mammalian cells. These two factors mean that this class of substituted thiazoles holds great promise as a future treatment for MRSA infections.

Advantages:

- Effective at preventing MRSA cell growth
- Does not harm mammalian cells

Potential Applications:

- Medical/Healthcare
- Medicinal Chemistry
- MRSA Treatment

People:

- Cushman, Mark (Project leader)
- Mayhoub, Abdelrahman S

- Seleem, Mohamed

Intellectual Property:

Application Date: April 29, 2016

Type: DIV-Patent

Country of Filing: United States

Patent Number: 9,801,861

Issue Date: October 31, 2017

Application Date: October 31, 2013

Type: Utility Patent

Country of Filing: United States

Patent Number: 9,353,072

Issue Date: May 31, 2016

Application Date: October 31, 2012

Type: Provisional-Patent

Country of Filing: United States

Patent Number: (None)

Issue Date: (None)

Contact OTC:

Purdue Office of Technology Commercialization

The Convergence Center

101 Foundry Drive, Suite 2500

West Lafayette, IN 47906

Phone: (765) 588-3475

Fax: (765) 463-3486

Email: otcip@prf.org